Garadacimab

Andembry

200 MG / 1.2 ML SolutionCanadaAuthorised

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Garadacimab

Andembry

200 MG / 1.2 ML SolutionCanadaAuthorised

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Netherlands · Oplossing voor injectie · CSL Behring GmbH

AndembryUnited States · 200MG/1.2ML · injectable · CSL Behring LLC

AndembryUnited States · 200MG/1.2ML · Injection · CSL Behring LLC

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Garadacimab
Strength: 200 MG / 1.2 ML
Dosage form: Solution
Route: Subcutaneous
Register: Canada (Health Canada)
Status: Authorised
Status in the register: Approved
Registration: DIN 02559765
Marketing authorisation holder: CSL Behring Canada INC
ATC code: B06AC07
Group: Blood and blood-forming organs
Supply: PRESCRIPTION, SCHEDULE D